Your browser doesn't support javascript.
loading
Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.
Abri Aghdam, Kaveh; Reznicek, Lukas; Soltan Sanjari, Mostafa; Framme, Carsten; Bajor, Anna; Klingenstein, Annemarie; Kernt, Marcus; Seidensticker, Florian.
Afiliación
  • Abri Aghdam K; Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany.
  • Reznicek L; Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.
  • Soltan Sanjari M; Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Sattarkhan-Niayesh Street, Tehran 14456-13131, Iran.
  • Framme C; Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany.
  • Bajor A; Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany.
  • Klingenstein A; Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.
  • Kernt M; Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.
  • Seidensticker F; Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany; Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.
Int J Ophthalmol ; 9(6): 858-62, 2016.
Article en En | MEDLINE | ID: mdl-27366688
AIM: To evaluate the association between the size of peripheral retinal non-perfusion and the number of intravitreal ranibizumab injections in patients with treatment-naive branch retinal vein occlusion (BRVO) and macular edema. METHODS: A total of 53 patients with treatment-naive BRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical coherence tomography (OCT) imaging and ultra wide-field fluorescein angiography (UWFA). Monthly intravitreal ranibizumab injections were applied according to the recommendations of the German Ophthalmological Society. Two independent, masked graders quantified the areas of peripheral retinal non-perfusion. RESULTS: Intravitreal injections improved best-corrected visual acuity (BCVA) significantly from 22.23±16.33 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters to 36.23±15.19 letters (P<0.001), and mean central subfield thickness significantly reduced from 387±115 µm to 321±115 µm (P=0.01). Mean number of intravitreal ranibizumab injections was 3.61±1.56. The size of retinal non-perfusion correlated significantly with the number of intravitreal ranibizumab injections (R=0.724, P<0.001). CONCLUSION: Peripheral retinal non-perfusion in patients with BRVO associates significantly with intravitreal ranibizumab injections in patients with BRVO and macular edema.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Int J Ophthalmol Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Int J Ophthalmol Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: China